Although recent studies did not prominently feature melittin nanoparticle systems co-delivered with standard CRC chemotherapeutics such as 5-fluorouracil or oxaliplatin, nor did they include targeting ligands against markers like EGFR [83], the demonstrated efficacy of melittin nanocarriers [27,41] and the potent anti-metastatic mechanisms of melittin [82] strongly support the continued development of advanced nanoparticle strategies for CRC treatment. Here, EGFR is linked to colorectal carcinoma.